Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes

Drug Metabolism and Disposition

Volumn 24, Issue 9, 1996, Pages 955-961

  Ekström, Gunilla ^a   Gunnarsson, Ulla Britt ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; CYTOCHROME P450 ISOENZYME; DIETHYLDITHIOCARBAMIC ACID; DRUG METABOLITE; ENZYME INHIBITOR; LOCAL ANESTHETIC AGENT; QUINIDINE; ROPIVACAINE; SULFAPHENAZOLE; TROLEANDOMYCIN;

ARTICLE; DRUG METABOLISM; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL;

AMIDES; ANESTHETICS, LOCAL; ARYL HYDROCARBON HYDROXYLASES; BENZOFLAVONES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOENZYMES; KINETICS; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; QUINIDINE; SUBSTRATE SPECIFICITY; TROLEANDOMYCIN;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0029833259     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. G. R. Arthur, H. S. Feldman, and B. G. Covino: Comparative pharmacokinetics of bupivacaine and ropivacaine, a new amide local anesthetic. Anesth. Analg. 67, 1053-1058 (1988).
2. A. Lee, D. Fagan, M. Lamont, G. T. Tucker, M. Halldin, and D. B. Scott: Disposition kinetics of ropivacaine in humans. Anesth. Analg. 69, 736-738 (1989).
3. J. A. Katz, P. O. Bridenbaugh, D. C. Knarr, S. H. Helton, and D. D. Denson: Pharmacodynamics and pharmacokinetics of epidural ropivacaine in humans. Anesth. Analg. 70, 16-21 (1990).
4. H. S. Feldman: Toxicity of local anesthetic agents. In "Anesthetic Toxicity" (S. A. Rice and K. J. Fish, eds.), pp. 107-133. Raven Press, New York, 1994.
5. M. M. Halldin, E. Bredberg, B. Angelin, T. Arvidsson, Y. Askemark, S. Elofsson, and M. Widman: Metabolism and excretion of ropivacaine in humans. Drug Metab. Dispos. 24, 962-968 (1996).
6. T. Arvidsson, H. Forsmo-Bruce, and M. M. Halldin: Lack of metabolic racemisation of ropivacaine, determined by liquid chromatography using a chiral AGP column. Chirality 7, 272-277 (1994).
7. A. Somogyi and M. Muirhead: Pharmacokinetic interactions of cimetidine. Clin. Pharmacokinet. 12, 321-366 (1987).
8. F. P. Guengerich: Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem. Res. Toxicol. 3, 363-371 (1990).
9. D. Sesardic, A. R. Boobis, B. P. Murray, S. Murray, J. Segura, R. De la Torre, and D. S. Davies: Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br. J. Clin. Pharmacol. 29, 651-663 (1990).
10. 1. Chem. Res. Toxicol. 5, 202-210 (1992).
11. T. K. H. Chang, F. J. Gonzalez, and D. J. Waxman: Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch. Biochem. Biophys. 311, 437-442 (1994).
12. L. Koymans, N. P. E. Vermeule, S. A. B. E. van Acker, J. M. te Koppele, J. J. P. Heykants, K. Lavrijsen, W. Meuldermans, and G. M. Donné-Op den Kelder: A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem. Res. Toxicol. 5, 211-219 (1992).
13. S. G. Al-Dabbagh, J. R. Idle, and R. L. Smith: Animal modelling of human polymorphic drug oxidation: the metabolism of debrisoquine and phenacetin in rat inbred strains. J. Pharm. Pharmacol. 33, 161-164 (1981).
14. B.-M. Emanuelsson, J. Persson, S. Sandin, C. Alm, and L. L. Gustafsson: Intra- and interindividual variability in the pharmacokinetics of a local anesthetic, ropivacaine, after intravenous infusions in healthy subjects. Ther. Drug Monit., in press.
15. S. Kobayashi, S. Murray, D. Watson, D. Sesardic, D. S. Davies, and A. R. Boobis: The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochem. Pharmacol. 38, 2795-2799 (1989).
16. J.-O. Persson, Y. Terelius, and M. Ingelman-Sundberg: Cytochrome P-450-dependent formation of reactive oxygen radicals: isozyme-specific inhibition of P-450-mediated reduction of oxygen and carbon tetrachloride. Xenobiotica 20, 887-900 (1990).
17. S. J. Baldwin, J. C. Bloomer, G. J. Smith, A. D. Ayrton, S. E. Clarke, and R. J. Chenery: Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25, 261-270 (1995).
18. Y. Oda, K. Furuichi, K. Tanaka, T. Hiroi, S. Imaoka, A. Asada, M. Fujimori, and Y. Funae: Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450. Anesthesiology 82, 213-220 (1995).
19. M. J. Bargetzi, T. Aoyama, F. J. Gonzalea, and U. A. Meyer: Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin. Pharmacol. Ther. 46, 521-527 (1989).
20. S. Imaoka, K. Enomoto, Y. Oda, A. Asada, M. Fujimori, T. Shimada, S. Fujita, F. P. Guengerich, and Y. Funae: Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450.S. J. Pharmacol. Exp. Ther. 255, 1385-1391 (1990).
21. S. A. Wrighton, C. Campanile, P. E. Thomas, S. L. Maines, P. B. Watkins, G. Parker, G. Mendez-Picon, M. Haniu, J. E. Shively, W. Levin, and P. S. Guzelian: Identification of a human liver cytochrome P-450 homologous to the major isosafrole-inducible cytochrome P-450 in the rat. Mol. Pharmacol. 29, 405-410 (1986).
22. K. Brøsen, E. Skjelbo, B. B. Rasmussen, H. E. Poulsen, and S. Loft: Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 45, 1211-1214 (1993).
23. O. Spigset, L. Carleborg, K. Hedenmalm, and R. Dahlqvist: Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin. Pharmacol. Ther. 58, 399-403 (1995).
24. S. A. Wrighton and J. C. Stevens: The human hepatic cytochromes P450 involved in drag metabolism. Crit. Rev. Toxicol. 22, 1-21 (1992).